Skip to content

Abstract 10761: Cardiac Biomarkers, Cardiovascular and Kidney Outcomes in Type 2 Diabetes: A Post-Hoc Analysis of the Look AHEAD Cardiac Biomarker Ancillary Study

Nov 2026 · Circulation · 0 citations

Abstract

Background: In the Look AHEAD trial, an intensive lifestyle intervention (ILI) reduced the risk of chronic kidney disease (CKD) in type 2 diabetes (T2D). Adults with CKD have higher concentrations of N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (hs-cTnT). Whether CKD modifies the effect of an ILI on these cardiac biomarkers and their associations with cardiovascular disease (CVD) risk is unknown. Whether these cardiac biomarkers identify participants who benefit from the ILI with reduced CKD risk is unknown. Methods: Look AHEAD trial participants were classified as having CKD if estimated glomerular filtration rate <60 ml/min/1.73m 2 or urine albumin-to-creatinine ratio ≥30 mg/g. The effects of the ILI targeting weight loss versus diabetes support and education (DSE) on NT-proBNP and hs-cTnT were assessed using adjusted geometric mean ratios (aGMRs), including tests for interaction by CKD status and corresponding stratified analyses. Adjusted Cox models were created to evaluate (1) the associations of NT-proBNP and hs-cTnT with CVD risk and (2) the effect of the ILI versus DSE on risk of very-high-risk CKD (see Figure legend for outcome definitions). Interaction testing was performed to assess whether CKD status modified the associations of NT-proBNP and hs-cTnT with CVD risk and whether baseline cardiac biomarkers modified the effect of the ILI on risk of very-high-risk CKD, with corresponding subgroup analyses. Results: 3,775 participants were included (59.4% women, 19.6% with CKD). CKD status did not modify the effect of the ILI on NT-proBNP or hs-cTnT ( p-interaction >0.05 for both). Among participants without CKD, the ILI versus DSE reduced hs-cTnT over 1- and 4-year follow-up and led to a transient increase in NT-proBNP at 1- but not 4-year follow-up. Similar findings were observed in the CKD subgroup ( Figure 1 ). Higher concentrations of NT-proBNP and hs-cTnT at baseline were significantly associated with higher risk of CVD events, irrespective of CKD strata ( p-interaction >0.05 for both) ( Figure 2 ). The effect of the ILI on risk of very-high-risk CKD varied according to baseline NT-proBNP, but not hs-cTnT. Compared with the DSE, the ILI reduced the risk of very-high-risk CKD among participants with NT-proBNP ≥125 pg/dL (hazard ratio [HR] 0.43, 95% CI: 0.25-0.75) but not those with NT-proBNP <125 pg/mL (HR 0.90, 95% CI: 0.64-1.26) ( p-interaction = 0.02) ( Figure 3 ). Conclusion: Among Look AHEAD trial participants with T2D, higher NT-proBNP and hs-cTnT were associated with higher risk of CVD events irrespective of CKD status. Elevated NT-proBNP identified a subgroup that had reduced risk of progression to very-high-risk CKD with the ILI.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.